Jazz Pharma adds cannabis-based drug to its portfolio
Posted in Industry News on 4th Feb 2021
Ireland-based Jazz Pharmaceuticals has agreed to buy UK company GW Pharmaceuticals, thus adding a cannabis-based epilepsy treatment to the sleep and cancer products already in its neuroscience unit.
Doctors in the UK have been able to prescribe GW Pharma’s Epidiolex since January 2020. The medicine is used to treat two severe forms of epilepsy – Lennox Gastaut syndrome and Dravet syndrome – and is available for children above the age of two and adults who are eligible.
Bruce Cozadd, Chairman and CEO of Jazz Pharmaceuticals, said:
Jazz is proud of our leadership position in sleep medicines and rapidly growing oncology business. We are excited to add GW’s industry-leading cannabinoid platform, innovative pipeline and products, which will strengthen and broaden our neuroscience portfolio, further diversify our revenue and drive sustainable, long-term value creation opportunities.”